Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Daniela Krause

Showing results (21-30 of 36) with videos related to

Pageof 4
Sort By:
Frontiers in Public Health|June 24, 2021
Just "Like Coffee" or Neuroenhancement by Stimulants?Andreas G Franke, Gabriele Koller, Daniela Krause, et al.
Clinical EEG and Neuroscience|November 28, 2018
Event-Related Potentials Are Associated With Unexpected Gain and Loss: Using a Gambling ParadigmDaniela Krause, Andrea Jobst, Shari Marie Langemak, et al.
Experimental and Clinical Psychopharmacology|May 23, 2022
Binding potential changes of SERT in patients with depression are associated with remission: A prospective [¹²³I]β-CIT-SPECT studyDaniela Krause, Agnieszka Chrobok, Susanne Karch, et al.
European Addiction Research|November 14, 2018
The Impact of the Opioid Antagonist Naloxone on Experimentally Induced Craving in Nicotine-Dependent IndividualsDaniela Krause, Marc Warnecke, Christian G Schuetz, et al.
Schizophrenia Research|June 24, 2010
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatmentNorbert Müller, Daniela Krause, Sandra Dehning, et al.
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|January 29, 2019
Values of Cytokines and Tryptophan Metabolites over a 12 Weeks Time Course in Patients with Depression and Somatoform DisorderDaniela Krause, Verena B Kirnich, Theresa M Stapf, et al.
Psychiatry Research|October 20, 2019
Methamphetamine withdrawal and the restoration of cognitive functions - a study over a course of 6 months abstinenceLisa Proebstl, Daniela Krause, Felicia Kamp, et al.
Substance Use & Misuse|February 4, 2017
High Concomitant Misuse of Fentanyl in Subjects on Opioid Maintenance TreatmentDaniela Krause, Diana Plörer, Gabriele Koller, et al.
Neuroimmunomodulation|June 13, 2018
Stability of Cellular Immune Parameters over 12 Weeks in Patients with Major Depression or Somatoform Disorder and in Healthy ControlsDaniela Krause, Theresa M Stapf, Verena B Kirnich, et al.
World Journal of Psychiatry|September 2, 2022
Treatment outcome, cognitive function, and psychopathology in methamphetamine users compared to other substance usersNina Behle, Felicia Kamp, Lisa Proebstl, et al.
Pageof 4

Showing results (21-30 of 36) with videos related to

Sort By:
Pageof 4
Frontiers in Public Health|June 24, 2021
Just "Like Coffee" or Neuroenhancement by Stimulants?Andreas G Franke, Gabriele Koller, Daniela Krause, et al.
Clinical EEG and Neuroscience|November 28, 2018
Event-Related Potentials Are Associated With Unexpected Gain and Loss: Using a Gambling ParadigmDaniela Krause, Andrea Jobst, Shari Marie Langemak, et al.
Experimental and Clinical Psychopharmacology|May 23, 2022
Binding potential changes of SERT in patients with depression are associated with remission: A prospective [¹²³I]β-CIT-SPECT studyDaniela Krause, Agnieszka Chrobok, Susanne Karch, et al.
European Addiction Research|November 14, 2018
The Impact of the Opioid Antagonist Naloxone on Experimentally Induced Craving in Nicotine-Dependent IndividualsDaniela Krause, Marc Warnecke, Christian G Schuetz, et al.
Schizophrenia Research|June 24, 2010
Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatmentNorbert Müller, Daniela Krause, Sandra Dehning, et al.
Clinical Psychopharmacology and Neuroscience : the Official Scientific Journal of the Korean College of Neuropsychopharmacology|January 29, 2019
Values of Cytokines and Tryptophan Metabolites over a 12 Weeks Time Course in Patients with Depression and Somatoform DisorderDaniela Krause, Verena B Kirnich, Theresa M Stapf, et al.
Psychiatry Research|October 20, 2019
Methamphetamine withdrawal and the restoration of cognitive functions - a study over a course of 6 months abstinenceLisa Proebstl, Daniela Krause, Felicia Kamp, et al.
Substance Use & Misuse|February 4, 2017
High Concomitant Misuse of Fentanyl in Subjects on Opioid Maintenance TreatmentDaniela Krause, Diana Plörer, Gabriele Koller, et al.
Neuroimmunomodulation|June 13, 2018
Stability of Cellular Immune Parameters over 12 Weeks in Patients with Major Depression or Somatoform Disorder and in Healthy ControlsDaniela Krause, Theresa M Stapf, Verena B Kirnich, et al.
World Journal of Psychiatry|September 2, 2022
Treatment outcome, cognitive function, and psychopathology in methamphetamine users compared to other substance usersNina Behle, Felicia Kamp, Lisa Proebstl, et al.
Pageof 4